Abstract:Introduction:Thrombocytopenia is a common complication after hematopoietic stem cell transplantation (HSCT) and is strongly associated with transplant-related morbidity and mortality. According to the statistics, the incidence of post-HSCT thrombocytopenia is about 5%-37%. So far, there is no standard treatment regimen for thrombocytopenia after HSCT. Recombinant human thrombopoietin (rhTPO) can act on megakaryocytes alone and has been wildly used in clinical practice. Thrombopoietin receptor agonists (TPO-RAs), another type of drugs that can increase platelet count, has been available since 2008. It can bind to the TPO receptor and cause the conformational change of the receptor, and then activate the JAK2/STATE5 pathway to increase the proliferation of megakaryocyte progenitors and platelet production. There have been many prospective or retrospective studies discussing the efficacy and safety of rhTPO and TPO-RAs monotherapy in patients with thrombocytopenia. In clinical practice, it is very meaningful to clarify whether the combination of two types of drugs has a synergistic effect when one type of drug has poor efficacy. M ethods This study is a retrospective study in total 12 patients from 2022 to 2023. We selected a total of 6 patients who underwent HSCT in our center during the past year, and used rhTPO combined with avatrombopag to help platelet recovery as observation group. Then, 6 patients treated with rhTPO alone with no statistical difference at baseline were selected as the control group. The basic characteristics of these patients are shown in the table1. All the patients were informed and consented to use rhTPO+TPO-RA (avatrombopag) or rhTPO alone. If platelet count <20×10 9/L during treatment,which will be treated with platelet infusion. All the patients were treated with a modified BUCY regimen as the conditioning regimen and ATG+MMF+cyclosporine+short-range MTX were used to prevent graft vs host disease (GVHD). In observation group, the patients were treated with rhTPO 15000U qd i.m and avatrombopag 40mg qd po, while in control group the patients were treated with rhTPO 15000U qd i.m alone. We recorded the platelet counts of the two groups at day0,7,14,21. Based on this data, the percentage increase and growth rate of platelets were calculated. (the percentage increase: difference in platelet count before and after medication/platelet count before medication ×100%; the growth rate: difference in platelet count before and after medication/duration of medication.) The above two values were used to evaluated the efficacy of two treatment protocols. Adverse events occurred during treatment including fever, weakness, liver damage, joint pain, bleeding and thrombosis would be recorded to evaluate the safety. Results In observation group, patients' platelet counts increased by an average was 54×10 9/L (range 40 to 69). In control group, the average and median increase in their platelet counts was 22 (range -2 to 49). P=0.025 (P<0.05). In terms of the percentage increase in platelet count, the average increase was 452% in observation group VS. 110% in control group. p=0.022(P<0.05). Refer to Figure1a. The average growth rates of platelet counts in observation group were 2.03×10 9/L per day. The averagerate of increase in control group were 1.07×109/L per day. P=0.041(P<0.05). The mean platelet count of the two groups at various time points were shown in Figure1b. None of the patients had any adverse events occurred. No patient developed clinical meaningful abnormality of liver function and discontinued avatrombopag or TPO treatment due to intolerability and adverse effects. Conclusion Our data shows that the treatment protocol of avatrombopag combined with rhTPO may have a greater effect on platelet growth and boost a faster platelet growth rate. Importantly, no additional adverse effects occurred when the addition of avatrombopag.

Effects of Thrombopoietin Pre-Treatment on Peri-Liver Transplantation Thrombocytopenia in a Mouse Model of Cirrhosis with Hypersplenism.

A Novel Recombinant Human Thrombopoietin for Treating Prolonged Isolated Thrombocytopenia after Allogeneic Stem Cell Transplantation.

[Preliminary Experimental Study on Treatment of Portal Hypertension with Auxiliary Partial Orthotopic Liver Transplantation].

Treatment of hypersplenism in perioperation of liver transplantation

Splenic Artery Trunk Embolization Reduces the Surgical Risk of Liver Transplantation

Protective Effect of Platelets Transfusion During Extracorporeal Circulation

Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B‐related cirrhosis: Multicentre real‐world observational study

[Effect of recombinant human thrombopoietin on platelets in rats with D-galactosamine salt-induced acute liver failure]

The Ersearch about Effect of Recombinant Human Thrombopoietin on Exsanguine Thronbocytopenia Mice

Thrombopoietin Enhances Hematopoietic Stem and Progenitor Cell Homing by Impeding Matrix Metalloproteinase 9 Expression

[Effect of Artificial Liver with Double Plasma Molecular Absorb System Model on Patients' Platelets and Corresponding Treatment Strategy].

Efficacy and Safety of Recombinant Human Thrombopoietin in Adult Patients with Primary Immune Thrombocytopenia During the Perioperative Period

Thrombocytopenia Predicts Poor Prognosis of Liver Transplantation

Effects of Liver Transplantation on Function and Morphological Changes of Spleen in Hepatic Cirrhosis Rat

Effect of Splenectomy on Coagulation and Platelet Function in Adult Liver Transplant Recipients Assessed With Rotational Thromboelastometry and Standard Coagulation Tests

Improved hepatic microcirculation by human soluble urinary thrombomodulin in the xeno-perfused porcine liver

Recombinant Human Thrombopoietin Combined with Thrombopoietin Receptor Agonists Can Facilitate the Recovery of Platelet after Allogeneic HSCT

Recombinant Human Thrombopoietin Improves Platelet Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: A Randomized, Controlled Clinical Trial

Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide

Platelet P-selectin and GPIIb/IIIa Expression after Liver Transplantation and Resection

Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.